CLSDQ

Clearside Biomedical, Inc. (NASDAQ:CLSD) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Alpharetta, Georgia. The company went public in 2016 and has positioned itself as a pioneer in developing a novel drug delivery method for treating eye diseases affecting the back of the eye, specifically through the suprachoroidal space. Clearside's primary focus is revolutionizing how medications are delivered to treat serious retinal conditions, with its lead commercial product XIPERE already approved and several promising candidates in clinical development.